Edition:
United Kingdom

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

27.38USD
9:00pm BST
Change (% chg)

$0.32 (+1.18%)
Prev Close
$27.06
Open
$27.66
Day's High
$27.66
Day's Low
$26.68
Volume
191,697
Avg. Vol
231,467
52-wk High
$43.98
52-wk Low
$13.51

Chart for

About

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $730.14
Shares Outstanding(Mil.): 26.98
Dividend: --
Yield (%): --

Financials

  ADMS.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -5.67 -- --
ROI: -67.05 -3.79 13.23
ROE: -92.17 -5.32 15.28

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

19 Apr 2018

BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment

* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon: Further company coverage:

03 Apr 2018

BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia

* ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

15 Mar 2018

BRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers

* ADAMAS PHARMACEUTICALS SAYS ‍AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING​

12 Mar 2018

BRIEF-Adamas Q4 Loss Per Share $1.27

* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017

22 Feb 2018

BRIEF-Adamas Announces Proposed Public Offering Of Common Stock

* ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

22 Jan 2018

Earnings vs. Estimates